Effectiveness of mechanical thrombectomy in cancer-related stroke and associated factors with unfavorable outcome
Open Access
- 6 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 21 (1), 1-10
- https://doi.org/10.1186/s12883-021-02086-y
Abstract
Background The effectiveness of mechanical thrombectomy (MT) in cancer-related stroke (CRS) is largely unknown. This study aims to investigate the clinical and radiological outcomes of MT in CRS patients. We also explored the factors that independently affect functional outcomes of patients with CRS after MT. Methods We retrospectively reviewed 341 patients who underwent MT after acute ischemic stroke onset between May 2014 and May 2020. We classified the patients into CRS (n = 34) and control (n = 307) groups and compared their clinical details. Among CRS patients, we analyzed the groups with and without good outcomes (3-months modified Rankin scale [mRS] score 0, 1, 2). Multivariate analysis was performed to investigate the independent predictors of unfavorable outcomes in patients with CRS after MT. Results A total of 341 acute ischemic stroke patients received MT, of whom 34 (9.9%) had CRS. Although the baseline National institute of health stroke scale (NIHSS) score and the rate of successful recanalization was not significantly different between CRS patients and control group, CRS patients showed more any cerebral hemorrhage after MT (41.2% vs. controls 23.8%, p = 0.037) and unfavorable functional outcome at 3 months (CRS patients median 3-month mRS score 4, interquartile range [IQR] 2 to 5.25 vs. controls median 3-month mRS score 3, IQR 1 to 4, [p = 0.026]). In the patients with CRS, elevated serum D-dimer level and higher baseline NIHSS score were independently associated with unfavorable functional outcome at 3 months (adjusted odds ratio [aOR]: 1.524, 95% confidence interval [CI]: 1.043–2.226; aOR: 1.264, 95% CI: 1.010–1.582, respectively). Conclusions MT is an appropriate therapeutic treatment for revascularization in CRS patients. However, elevated serum D-dimer levels and higher baseline NIHSS scores were independent predictors of unfavorable outcome. Further research is warranted to evaluate the significance of these predictors.This publication has 45 references indexed in Scilit:
- What Is Meant by “TICI”?American Journal of Neuroradiology, 2013
- Clues to Occult Cancer in Patients with Ischemic StrokePLOS ONE, 2012
- Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancerCritical Reviews in Clinical Laboratory Sciences, 2011
- Intravenous thrombolysis for acute stroke in patients with cancerJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Ischemic Stroke in Cancer Patients With and Without Conventional MechanismsStroke, 2010
- Predictors of Good Clinical Outcomes, Mortality, and Successful Revascularization in Patients With Acute Ischemic Stroke Undergoing ThrombectomyStroke, 2009
- Disseminated intravascular coagulation in cancer patientsBest Practice & Research Clinical Haematology, 2009
- Stroke and cancer: a reviewActa Neurologica Scandinavica, 2009
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988